Skip to main content

AMD

5
Pipeline Programs
8
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Regenxbio
RegenxbioMD - Rockville
2 programs
1
1
ABBV-RGX-314 Dose 1Phase 31 trial
ABBV-RGX-314Phase 2/31 trial
Active Trials
NCT04704921Active Not Recruiting671Est. Nov 2027
NCT05407636Recruiting714Est. Nov 2027
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
1
ABBV-RGX-314 Dose 1Phase 3
ABBV-RGX-314Phase 2/3
Tasly Pharmaceutical
Tasly PharmaceuticalChina - Tianjin
1 program
1
Sanhuang Jingshiming/Pills placeboPhase 31 trial
Active Trials
NCT07269769Not Yet Recruiting450Est. Dec 2031
Notal Vision
Notal VisionVA - Manassas
2 programs
NOTAL OCT V2.5N/A1 trial
NOTAL-OCT V3.0N/A1 trial
Active Trials
NCT03600519Completed87Est. Jan 2020
NCT04078672Completed58Est. Mar 2023
Bayer
BayerLEVERKUSEN, Germany
1 program
CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)N/A1 trial
Active Trials
NCT03803631Completed49Est. Nov 2021
Biolab Pharma
Biolab PharmaBrazil - São Paulo
1 program
Postbotics and VitaminsN/A1 trial
Active Trials
NCT05056025Unknown48Est. Jan 2024
Visufarma
VisufarmaNetherlands - Amsterdam
1 program
Visucomplex PlusN/A1 trial
Active Trials
NCT04177069Unknown160Est. Dec 2020
Lee's Pharmaceutical
Lee's PharmaceuticalChina - Guangzhou
1 program
TAB014PHASE_11 trial
Active Trials
NCT03675880Unknown24Est. Apr 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Tasly PharmaceuticalSanhuang Jingshiming/Pills placebo
RegenxbioABBV-RGX-314 Dose 1
RegenxbioABBV-RGX-314
Lee's PharmaceuticalTAB014
Biolab PharmaPostbotics and Vitamins
VisufarmaVisucomplex Plus
Notal VisionNOTAL-OCT V3.0
Notal VisionNOTAL OCT V2.5
BayerCNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)

Clinical Trials (9)

Total enrollment: 2,261 patients across 9 trials

NCT07269769Tasly PharmaceuticalSanhuang Jingshiming/Pills placebo

A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD

Start: Apr 2026Est. completion: Dec 2031450 patients
Phase 3Not Yet Recruiting
NCT05407636RegenxbioABBV-RGX-314 Dose 1

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Start: Jan 2022Est. completion: Nov 2027714 patients
Phase 3Recruiting
NCT04704921RegenxbioABBV-RGX-314

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

Start: Dec 2020Est. completion: Nov 2027671 patients
Phase 2/3Active Not Recruiting
NCT03675880Lee's PharmaceuticalTAB014

TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects

Start: Jun 2018Est. completion: Apr 201924 patients
Phase 1Unknown
NCT05056025Biolab PharmaPostbotics and Vitamins

Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration.

Start: Dec 2020Est. completion: Jan 202448 patients
N/AUnknown
NCT04177069VisufarmaVisucomplex Plus

Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD

Start: Dec 2019Est. completion: Dec 2020160 patients
N/AUnknown
NCT04078672Notal VisionNOTAL-OCT V3.0

Retinal Imaging Using NOTAL-OCT V3.0

Start: Dec 2019Est. completion: Mar 202358 patients
N/ACompleted
NCT03600519Notal VisionNOTAL OCT V2.5

Retinal Imaging Using NOTAL-OCT V2.5

Start: Jul 2018Est. completion: Jan 202087 patients
N/ACompleted
NCT03803631BayerCNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)

CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)

Start: Apr 2018Est. completion: Nov 202149 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 2,261 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.